Mast Therapeutics, Inc. (MSTX)

[Rhodey Red]

Another positive thought regarding New CMO appt.: just working on what would be logical... Mast Acquires Aires Pharma to add AIR001 to its pipeline. Mast is scheduled to release preliminary data from 29 patients in AIR001 Phase 2 trial within the next 21 trading days. Logic dictates that the data will be very positive and that the development plan for AIR001 will make sense individually and in concert with our existing pipeline studies.



RATIONALE: The hiring of Ed P. as our interim CMO from his previous CMO position at Aires Pharmaceutical logically points to the probability that the AIR data will be very positive.

It would make little sense to acquire a company if your inside research pre acquisition had determined that the data was poor.

It would make little sense to announce this data release and subsequent development plan if the inside information pre acquisition was that the data was poor.

It would make little sense to hire Ed P. as interim CMO (hence doubling down on Aires Performance) if he was most recently heading a clinical trial that was producing poor data.

Conclusion: the scheduled AIR001 data will be positive!!!!